新股消息 | 卓正医疗通过港交所聆讯 专注服务中高端医疗服务市场

Core Viewpoint - 卓正医疗控股有限公司 is focusing on the high-end medical service market in China, targeting affluent consumers who prefer personalized healthcare services, and is preparing for its listing on the Hong Kong Stock Exchange [1][4]. Company Overview - 卓正医疗 is the third-largest private high-end comprehensive medical service provider in China, with a market share of 2.0% based on projected revenues for 2024 [4]. - The company operates a network of 19 medical service institutions across major Chinese cities and has additional clinics in Singapore and Malaysia [5]. Market Analysis - The private high-end medical service market in China is projected to grow from RMB 193 billion in 2020 to RMB 426.3 billion by 2024, reflecting a compound annual growth rate (CAGR) of 21.9%. It is expected to continue growing at a CAGR of 14.3% from 2024 to 2029, reaching RMB 831.4 billion by 2029 [4]. - Private high-end medical service institutions are expected to account for approximately 66.5% of the total revenue in the high-end medical service market in China by 2024 [4]. Business Model - 卓正医疗 employs a family healthcare model that integrates both in-person and online medical services, enhancing patient satisfaction and facilitating cross-specialty referrals [6]. - The company has a structured talent development framework to attract and retain qualified medical professionals, with 387 full-time doctors averaging about 15 years of experience [6]. Financial Performance - Revenue figures for 卓正医疗 from 2022 to 2024 are as follows: RMB 473.2 million in 2022, RMB 690.4 million in 2023, and RMB 958.6 million in 2024, indicating a consistent upward trend [7]. - The company recorded net losses of RMB 222 million in 2022 and RMB 353 million in 2023, but achieved a profit of approximately RMB 80.2 million in 2024 [6][7].